A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor

Rheumatology (Oxford). 2016 Feb;55(2):382-4. doi: 10.1093/rheumatology/kev371. Epub 2015 Oct 15.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antiphospholipid Syndrome / diagnosis
  • Antiphospholipid Syndrome / drug therapy*
  • Antiphospholipid Syndrome / metabolism
  • Complement Activation / drug effects
  • Complement C5 / antagonists & inhibitors*
  • Complement C5 / metabolism
  • Disease Progression
  • Female
  • Humans
  • Recurrence
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement C5
  • eculizumab